ReviewCurrent oncology reports2018
Pseudoprogression of Melanoma Brain Metastases.
Review in Current oncology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Clinical and radiological features of pseudoprogression in brain tumors treated with immune checkpoint inhibitors.Journal of neuro-oncology · 2025Article
- Intratumoral hemorrhage from brain metastases following nivolumab therapy for malignant melanoma: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- A Case Report of Primary Pulmonary Lymphoepithelioma-Like Carcinoma with "Harmful" Pseudoprogression and a Pathological Complete Response (pCR) after Immunotherapy Plus Radiotherapy.Oncology research · 2025Article
- Article
- Response Assessment in Brain Metastases Managed by Stereotactic Radiosurgery: A Reappraisal of the RANO-BM Criteria.Current oncology (Toronto, Ont.) · 2023Article
- Dosimetric and clinical analysis of pseudo-progression versus recurrence after hypo-fractionated radiotherapy for brain metastases.Radiation oncology (London, England) · 2023Article
- Incorporating lesion-to-lesion heterogeneity into early oncology decision making.Frontiers in immunology · 2023Review
- Pulmonary Resection after Radiosurgery and Neoadjuvant Immunochemotherapy for NSCLC Patients with Synchronous Brain Metastasis-A Case Series of Three Patients.Current oncology (Toronto, Ont.) · 2022Article
- Volumetric Response of Limited Brain Metastatic Disease to Focal Hypofractionated Radiation Therapy.Brain sciences · 2021Article
- Treating Metastatic Brain Cancers With Stem Cells.Frontiers in molecular neuroscience · 2021Review
- Comprehensive Analysis of the Immune Implication of TEX41 in Skin Cutaneous Melanoma.Disease markers · 2021Article
- Review
- A simple score to estimate the likelihood of pseudoprogression vs. recurrence following stereotactic radiosurgery for brain metastases: The Bergen Criteria.Neuro-oncology advancesArticle
- Pseudoprogression and Immunotherapy Phenomena.Journal of the advanced practitioner in oncologyArticle
- Immunotherapy as a Turning Point in the Treatment of Melanoma Brain Metastases.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewImmune checkpoint inhibitors are increasingly being used to treat melanoma brain metastases. One potential complication of immune checkpoint inhibitors is a phenomenon called pseudoprogression, in which a tumor transiently increases in size due to lymphocyte infiltration. This article reviews the characteristics of pseudoprogression and their clinical implications. RECENT
findingsPseudoprogression can be challenging to differentiate from true progression noted clinically or radiographically, thereby complicating management decisions and potentially confusing patients and their families. The transient tumor enlargement can also cause symptoms that mimic true tumor progression. Because the use of immunotherapy on melanoma brain metastases is a relatively new treatment paradigm, there is limited evidence to guide clinical decision-making and prognostication related to pseudoprogression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.